20 episodes

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

Physician's Weekly Podcast Physician's Weekly

    • Health & Fitness
    • 5.0 • 2 Ratings

Physician's Weekly offers in-depth interviews with the most highly respected experts in the medical community, weighing in on landmark research, trending topics, and offering insight on issues affecting everyday medical practice. In collaboration with Medicom Medical Publishers, Physician's Weekly Podcast continues to maintain the company's nearly 40 year reputation as a trusted resource for healthcare professionals.

    Get Back to Patient Care With MSOs & Cilia’s Key Cancer Role

    Get Back to Patient Care With MSOs & Cilia’s Key Cancer Role

    Management Service Organizations (MSOs) can help you delegate the business side of medicine so you can focus on patient care. Dr. MedLaw explains, including, how MSOs factor into the corporate practice of medicine and more.
     
     Also, did you know cilia play an important role in early beginnings of cancer in neural crest cells? Lukas Sommer, PhD, discusses his teams' research in developmental and cell biology.

    Enjoy listening!
    https://www.anatomy.uzh.ch/en/research/sommer.html
    Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 2018 Jul 9;34(1):69-84.e14. 

    • 19 min
    Abortion Care, Access & Managing ADPKD-Associated Pain

    Abortion Care, Access & Managing ADPKD-Associated Pain

    Welcome to this episode of Physician’s Weekly podcast. I am your host, Dr. Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician’s Weekly. 
    In this episode, we have two fascinating interviews. Physician’s Weekly’s Editorial Board Member Alex McDonald, MD, interviews Kavita Arora, MD, Division Director of General Obstetrics and Gynecology, University of North Carolina School of Medicine  (https://www.med.unc.edu/obgyn/directory/kavita-aurora-md-mbe-ms/) about how to flip the narrative that providing abortion service *is* healthcare. In this interview Dr. Arora is “Not sure that I would agree that the measures are well-intended; I think they are misogynistic and controlling of women. They invade patient-clinician privacy and the sacred relationship that happens in my exam room.”
    But first,  Physician’s Weekly’s senior editor Martta Kelly speaks with Dr. Osama Amro, Director of Swedish Polycystic Kidney Disease Center in Seattle, WA, about their multidisciplinary patient-centered approach to pain management strategies in the management of autosomal dominant polycystic disease (ADPKD). ADPKD is one of the most common genetic diseases in humans, affecting 1 in 400 individuals, and is the fourth most common cause of renal failure worldwide.  If one parent has ADPKD, the children have a 50% chance of inheriting the gene (though up to 10% of patients don’t have a family history and have de novo mutations). Pain management is central to progressive ADPKD, as the cysts grow, the weight of the kidneys can affect other systems. Dr. Amro provides practical tips on both pharmacological and non-pharmacological approaches.
    Enjoy listening!

    • 23 min
    Biomarkers for NSCLC: What You Need to Know – Part 2

    Biomarkers for NSCLC: What You Need to Know – Part 2

    The evolution of biomarkers informing therapy decisions began in 2004, when the FDA approved a medicine to treat EGFR mutated non-small cell lung cancer (NSCLC). Since then, researchers have identified more than 20 distinct mutations in driver genes that are specific to lung cancer, nine of which are treatable through FDA-approved therapy drugs: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, BRAF V600E, NTRK, MET, RET, and histological expression of programmed death ligand 1 (PD-L1).
    Confirming a patient's biomarker status can open the door to precision medicine. 
    The molecular characterization of lung cancer has considerably changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has also led to accelerated development of new drugs for lung cancer treatment. Additional research is needed to identify and help treat the approximately one-third of lung cancer patients for whom biomarkers have yet to be identified.
    This podcast focuses on clinically relevant cancer biomarkers as targets for therapy, as well as potential new targets for drug development. We spoke in our first episode with Dr. David M. Waterhouse, who just moved to the Dana Farber Cancer Institute at Harvard Medical School, and until last month was the former Director of Clinical Research at Oncology-Hematology Care, in Cincinnati. We also talk about how these biomarkers are used in academic versus community hospitals. In this second episode, we talk with Dr. Sinchita Roy Chowdhuri, a molecular pathologist from University of Texas MD Anderson Cancer Center, about what you didn’t know about actionable biomarkers for NSCLC.

    • 16 min
    An inDEPTH Look at Chronic Myeloid Leukemia

    An inDEPTH Look at Chronic Myeloid Leukemia

    To acknowledge the Philadelphia Chromosome translocation t(9;22) in chronic myeloid leukemia (CML), every September 22 (9/22) is World CML Day. Today’s podcast episode looks at this topic through different lenses. First, two members of the Lancet Haematology’s committee on adverse events—Jan Geissler, co-founder of the CML Advocates Network, and Gita Thanarajasingam, MD, the committee chair and a hematologist at the Mayo Clinic—discuss how side effects are reported and analyzed and how the committee intends to change that. Geissler also talks about how his experience as a patient with CML led him to become and expert advocate.
     
    Additional reading:
    Geissler J, Huber S. Improving outcomes through patient-generated evidence-the next step in patient advocacy. Lancet Haematol. 2022 Jun;9(6):e399-e400. 
    Thanarajasingam G, et al. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384
    Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198. 

    • 26 min
    An inDEPTH Look at Lymphoma

    An inDEPTH Look at Lymphoma

    September 15 is World Lymphoma Awareness Day, with the theme We Can’t Wait. To honor the leaps and bounds that research into this rare cancer has made, today’s podcast views the current state of lymphoma through different lenses. First, Dr. Constantine Tam, Head of Lymphoma Service at Alfred Hospital and Professor of Hematology at Monash University in Melbourne, Australia talks about the SEQUOIA trial on the efficacy of BTK inhibitor zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, recently published in Lancet Oncology. 
    Also, Lorna Warwick, CEO of the Lymphoma Coalition, based in Canada as a federation of more than 80 lymphoma patient organizations worldwide that runs the World Lymphoma Awareness Day project, discusses the more than 80 subtypes of non-Hodgkin’s lymphoma. She has some great insights into the unmet needs of patients with lymphoma and how to budge the needle on care.
    Enjoy listening!

    • 24 min
    inDEPTH: What OTC Hearing Aids & Rural Alaska Have in Common

    inDEPTH: What OTC Hearing Aids & Rural Alaska Have in Common

    Today’s episode features two interviews, taking different lenses on news in hearing loss. We first talk with Frank Lin, MD, PhD, at the Johns Hopkins School of Medicine about the various obstacles to hearing health, including new advice on the just FDA-approved OTC hearing aids. He has been part of the FDA rule from the start and tells us a little about how this came to be, as well as some of the benefits. We then speak with Susan D. Emmett, MD, MPH, from the University of Arkansas. She recently led a randomized controlled trial in 15 communities in rural Alaska, looking at whether telemedicine specialty referral can improve time to follow-up for school hearing screening compared with standard primary care referral. Enjoy listening!
     
    Additional reading
     
    Lin FR, Reed NS. Over-the-counter hearing aids: How we got here and necessary next steps. J Am Geriatr Soc. 2022 Jul;70(7):1954-1956. 
     
    Emmett SD, et al. Mobile health school screening and telemedicine referral to improve access to specialty care in rural Alaska: a cluster- randomised controlled trial. Lancet Glob Health. 2022 Jul;10(7):e1023-e1033
     

    • 22 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings